The Burrill Report


The Burrill Report (March 11, 2013): A Proof-of-Concept for Fast Exit Strategy (.MP3,15.29 Mb)



It was about two years ago when we first sat down with Jim Posada to discuss his company Resolve Therapeutics and his pursuit of a business model that could combat the long road to an exit for investors and entrepreneurs. Now, Resolve has entered into an agreement with Takeda Pharmaceuticals for development of RSLV-132, the company’s experimental lupus drug. The deal provides Resolve $8 million upfront and a potential of up to $247 million in milestones, as well as royalty payments. We spoke to Posada about the deal, how it provides a proof-of-concept for his business model, and what he has learned along the way.

March 08, 2013
http://www.burrillreport.com/article-a_proof_of_concept_for_fast_exit_strategy.html